Schedule 13D ownership disclosure

KINNATE BIOPHARMA INC

Security class unavailable · CUSIP: 49705R105

Event date: 2020-12-03

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
9,671,643
Percent of class
22.3000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-20-135408
Form type
SC 13D
Filer
Foresite Capital Fund IV, L.P.
CIK
CIK 1704131
Filed
Dec 15, 2020
Reporting period
Dec 03, 2020
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub